Background— Secondary prevention after acute myocardial infarction (AMI) is achieved
primarily through medications. However, patients must take their medications to benefit. …

ContextLandmark clinical trials have demonstrated the survival benefits of statins, with benefits
usually starting after 1 to 2 years of treatment. Research prior to these trials of older lipid-…

Background : The prognostic importance of high-density lipoprotein cholesterol (HDL-C) as
a specific risk factor for cardiovascular (CV) disease has been challenged by recent clinical …

Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation (AF)
is dependent on adherence and persistence in the real-world setting. Individual study …

Background— Current observational studies on warfarin use and the risk for stroke and
bleeding in patients with atrial fibrillation (AF) undergoing dialysis found conflicting results. …

Context Stroke is a serious complication associated with atrial fibrillation (AF). Women with
AF are at higher risk of stroke compared with men. Reasons for this higher stroke risk in …

Background Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in
patients with non-valvular atrial fibrillation (NVAF). It does not require routine monitoring with …

Background: Pay-for-performance (P4P) is increasingly touted as a means to improve
health care quality. Purpose: To evaluate the effect of P4P remuneration targeting individual …

Background Controversy continues concerning the choice of rhythm control vs rate control
treatment strategies for atrial fibrillation (AF). A recent clinical trial showed no difference in 5-…

Background— The CArdiovascular HEalth in Ambulatory care Research Team (CANHEART)
is conducting a unique, population-based observational research initiative aimed at …